Neuphoria Therapeutics Stock Forecast - Simple Moving Average
| NEUP Stock | 4.17 0.13 3.22% |
The Simple Moving Average forecasted value of Neuphoria Therapeutics on the next trading day is expected to be 4.11 with a mean absolute deviation of 0.13 and the sum of the absolute errors of 7.80. Neuphoria Stock Forecast is based on your current time horizon.
As of today, the value of RSI of Neuphoria Therapeutics' share price is approaching 43. This indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Neuphoria Therapeutics, making its price go up or down. Momentum 43
Sell Extended
Oversold | Overbought |
Using Neuphoria Therapeutics hype-based prediction, you can estimate the value of Neuphoria Therapeutics from the perspective of Neuphoria Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Moving Average forecasted value of Neuphoria Therapeutics on the next trading day is expected to be 4.11 with a mean absolute deviation of 0.13 and the sum of the absolute errors of 7.80. Neuphoria Therapeutics after-hype prediction price | USD 4.17 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Neuphoria | Build AI portfolio with Neuphoria Stock |
Neuphoria Therapeutics Additional Predictive Modules
Most predictive techniques to examine Neuphoria price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Neuphoria using various technical indicators. When you analyze Neuphoria charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Neuphoria Therapeutics Simple Moving Average Price Forecast For the 23rd of January
Given 90 days horizon, the Simple Moving Average forecasted value of Neuphoria Therapeutics on the next trading day is expected to be 4.11 with a mean absolute deviation of 0.13, mean absolute percentage error of 0.04, and the sum of the absolute errors of 7.80.Please note that although there have been many attempts to predict Neuphoria Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Neuphoria Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Neuphoria Therapeutics Stock Forecast Pattern
| Backtest Neuphoria Therapeutics | Neuphoria Therapeutics Price Prediction | Buy or Sell Advice |
Neuphoria Therapeutics Forecasted Value
In the context of forecasting Neuphoria Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Neuphoria Therapeutics' downside and upside margins for the forecasting period are 0.04 and 9.46, respectively. We have considered Neuphoria Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of Neuphoria Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Neuphoria Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 111.1951 |
| Bias | Arithmetic mean of the errors | 0.0247 |
| MAD | Mean absolute deviation | 0.1322 |
| MAPE | Mean absolute percentage error | 0.0305 |
| SAE | Sum of the absolute errors | 7.8 |
Predictive Modules for Neuphoria Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neuphoria Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuphoria Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuphoria Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Neuphoria Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Neuphoria Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Neuphoria Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Neuphoria Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Neuphoria Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Neuphoria Therapeutics' historical news coverage. Neuphoria Therapeutics' after-hype downside and upside margins for the prediction period are 0.21 and 9.53, respectively. We have considered Neuphoria Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Neuphoria Therapeutics is risky at this time. Analysis and calculation of next after-hype price of Neuphoria Therapeutics is based on 3 months time horizon.
Neuphoria Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Neuphoria Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuphoria Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Neuphoria Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.51 | 5.36 | 0.01 | 0.01 | 6 Events / Month | 3 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
4.17 | 4.17 | 0.00 |
|
Neuphoria Therapeutics Hype Timeline
Neuphoria Therapeutics is now traded for 4.17. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.01. Neuphoria is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is now at -0.51%. %. The volatility of related hype on Neuphoria Therapeutics is about 31529.41%, with the expected price after the next announcement by competition of 4.16. About 46.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neuphoria Therapeutics recorded a loss per share of 4.02. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 24th of December 2024. Given the investment horizon of 90 days the next anticipated press release will be in about 6 days. Check out Historical Fundamental Analysis of Neuphoria Therapeutics to cross-verify your projections. To learn how to invest in Neuphoria Stock, please use our How to Invest in Neuphoria Therapeutics guide.Neuphoria Therapeutics Related Hype Analysis
Having access to credible news sources related to Neuphoria Therapeutics' direct competition is more important than ever and may enhance your ability to predict Neuphoria Therapeutics' future price movements. Getting to know how Neuphoria Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Neuphoria Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PTHL | Pheton Holdings Ltd | 0.00 | 0 per month | 4.04 | 0.09 | 10.91 | (6.67) | 22.91 | |
| IINN | Inspira Technologies Oxy | (0.01) | 2 per month | 0.00 | (0.11) | 6.86 | (6.96) | 24.08 | |
| BMRA | Biomerica | 0.02 | 4 per month | 0.00 | (0.08) | 4.12 | (4.98) | 18.44 | |
| PFSA | Profusa Common Stock | 0.00 | 0 per month | 0.00 | (0.05) | 12.50 | (17.65) | 91.67 | |
| APRE | Aprea Therapeutics | (0.11) | 8 per month | 0.00 | (0.24) | 4.44 | (8.40) | 17.87 | |
| CHEK | Check Cap | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| LUCY | Innovative Eyewear | 0.00 | 0 per month | 0.00 | (0.02) | 9.70 | (9.83) | 57.39 | |
| BCDA | Biocardia | (0.06) | 8 per month | 0.00 | (0.05) | 5.93 | (5.76) | 21.46 | |
| ALZN | Alzamend Neuro | 0.00 | 0 per month | 0.00 | (0.04) | 6.10 | (5.33) | 20.82 | |
| LFWD | ReWalk Robotics | (0.01) | 2 per month | 4.37 | 0.03 | 10.14 | (6.58) | 34.28 |
Other Forecasting Options for Neuphoria Therapeutics
For every potential investor in Neuphoria, whether a beginner or expert, Neuphoria Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Neuphoria Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Neuphoria. Basic forecasting techniques help filter out the noise by identifying Neuphoria Therapeutics' price trends.Neuphoria Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neuphoria Therapeutics stock to make a market-neutral strategy. Peer analysis of Neuphoria Therapeutics could also be used in its relative valuation, which is a method of valuing Neuphoria Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Neuphoria Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Neuphoria Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neuphoria Therapeutics shares will generate the highest return on investment. By undertsting and applying Neuphoria Therapeutics stock market strength indicators, traders can identify Neuphoria Therapeutics entry and exit signals to maximize returns.
Neuphoria Therapeutics Risk Indicators
The analysis of Neuphoria Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Neuphoria Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting neuphoria stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.28 | |||
| Standard Deviation | 5.36 | |||
| Variance | 28.71 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Neuphoria Therapeutics
The number of cover stories for Neuphoria Therapeutics depends on current market conditions and Neuphoria Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Neuphoria Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Neuphoria Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Neuphoria Therapeutics Short Properties
Neuphoria Therapeutics' future price predictability will typically decrease when Neuphoria Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Neuphoria Therapeutics often depends not only on the future outlook of the potential Neuphoria Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neuphoria Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.6 M | |
| Cash And Short Term Investments | 14.2 B |
Additional Tools for Neuphoria Stock Analysis
When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.